# Jason Whitmire

> Jason Whitmire is a Series A investor at BlueYard Capital backing Analytics and Biotechnology. See 25 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BlueYard Capital](https://shizune.co/investors/profile/blueyard-capital)
- Location: Berlin, Germany
- Total investments: 25
- Last investment: Sep 2024
- Lead investor: 48%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/jasonwhitmire
- X (Twitter): http://twitter.com/jason_whitmire
- Website: https://www.blueyard.com/

Jason Whitmire is a Series A investor at BlueYard Capital in Berlin focused on Analytics and Biotechnology. Jason Daniel Whitmire is based out of New York and is the General Partner and Co-founder of BlueYard Capital. Jason previously worked at Earlybird Venture Capital as a partner.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Analytics | 5 | 20% |
| Biotechnology | 5 | 20% |
| Big Data | 3 | 12% |
| Artificial Intelligence | 3 | 12% |
| SaaS | 2 | 8% |

45 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 40% |
| Series B | 5 | 20% |
| Seed | 3 | 12% |
| Pre-Seed | 2 | 8% |
| Series C | 1 | 4% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 5 | 20% |
| United States | 4 | 16% |
| Mexico | 1 | 4% |
| Sweden | 1 | 4% |
| Denmark | 1 | 4% |

7 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CPTx | CPTx develops single-stranded DNA products to neutralize viruses and address infectious diseases. | $29M | Venture - Series Unknown | Sep 12, 2024 |  |
| Insempra | Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance. | $20M | Series A | May 07, 2024 |  |
| Zafrens | Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States. | $23M | Series A | Dec 11, 2023 |  |
| Biomia | Biomia is a synthetic biology company developing plant-derived natural products for unmet medical needs in pain, addiction, and depression. | $3M | Pre-Seed | Sep 26, 2023 |  |
| Meatable | Meatable is a food production company that produces guilt-free meat. Meatable is a company that creates manufactured meat using stem cell technology. By employing pluripotent stem cells, which have the potential to transform any type of cell from muscle to fat without serum, the company's method eliminates the need to remove any tissue from ananimal, allowing consumers to have sustainable food. | $34M | Series B | Aug 07, 2023 |  |
| Chemify | Digitising Chemistry and Chemical Discovery | $47.1M | Series A | Aug 02, 2023 |  |
| Sensible Biotechnologies | Sensible Biotechnologies is developing world's first cell-based platform to unlock the next generation of mRNA medicines. | $3.8M | Pre-Seed | Apr 06, 2023 |  |
| Insempra | Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance. | $15M | Series A | May 25, 2021 |  |
| Insempra | Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance. | $15M | Seed | May 25, 2021 |  |
| Meatable | Meatable is a food production company that produces guilt-free meat. Meatable is a company that creates manufactured meat using stem cell technology. By employing pluripotent stem cells, which have the potential to transform any type of cell from muscle to fat without serum, the company's method eliminates the need to remove any tissue from ananimal, allowing consumers to have sustainable food. | $47M | Series A | Mar 23, 2021 |  |

10 of 25 investments shown.

## Co-investors
- [EQT Ventures](https://shizune.co/investors/profile/eqtventures) — VC Fund, 7 deals together
- [Possible Ventures](https://shizune.co/investors/profile/possible-ventures) — VC Fund, 7 deals together
- [OpenOcean](https://shizune.co/investors/profile/open-ocean) — VC Fund, 4 deals together
- [Acequia Capital (AceCap)](https://shizune.co/investors/profile/acequia-capital) — VC Fund, 2 deals together
- [Agronomics](https://shizune.co/investors/profile/agronomics-d560) — VC Fund, 2 deals together
- [Alix Ventures](https://shizune.co/investors/profile/alix-ventures) — VC Fund, 2 deals together

## About BlueYard Capital

VC Fund · Berlin, Germany

BlueYard invests in founders with transforming ideas that decentralize markets and empower humanity. Typically $1-3m as an initial investment; active around the world. Most active in crypto / web 3 (e.g. Protocol Labs, Filecoin, Open Zeppelin, Radicle), technologies that help us overcome our largest planetary challenges (e.g. Marvel Fusion,Meatable, Dance), frontier biology to help us live long and prosper (e.g. BitBio, Biofidelity) and vertical software un-bundling monopolies (e.g. Pitch, Wonder).

5 contacts available at BlueYard Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Chad Fowler | General Manager | https://shizune.co/investors/profile/chad-fowler |
| Ciarán O'Leary | General Partner and Co-Founder | https://shizune.co/investors/profile/ciarn-oleary |
| David Byrd | Venture Partner | https://shizune.co/investors/profile/david-byrd |
| Jason Whitmire | General Partner and Co-Founder | https://shizune.co/investors/profile/jason-whitmire |
| Philipp Hartmann | Venture Partner | https://shizune.co/investors/profile/philipp-hartmann-2 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jason Whitmire invest in?

Jason Whitmire invests primarily in Analytics, Biotechnology and Big Data startups, most often at Series A and Series B stage. Most of the 25 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jason Whitmire last invest?

The most recent investment recorded for Jason Whitmire closed in Sep 2024. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co